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Abstract
The lysosomal storage disorders are a group of inherited metabolic diseases each characterised by a relative or absolute
deficiency of one or more of the lysosomal proteins involved in the hydrolysis of glycoconjugates or in the transport of the
resulting product. Enzyme replacement therapies are under consideration for a number of these disorders and are based on
the in vitro observation that cells from affected patients can be corrected by addition of exogenous enzyme. In this study,
 . two glycosylation variants of the lysosomal enzyme N-acetylgalactosamine-4-sulphatase 4S the deficiency of which
 .  .causes Mucopolysaccharidosis MPS type VI, Maroteaux–Lamy syndrome were made by expression of 4S cDNA in both
 .  .wild type chinese hamster ovary CHO-K1 , and Lec1 N-acetylglucosaminyltransferase I deficient CHO-K1 cells.
Differences in the glycosylation pattern of the two enzyme forms were demonstrated with endoglycosidase H and
N-glycosidase F digestions. The receptor mediated binding of these two forms of 4S to two cell types, human skin
fibroblasts and rat alveolar macrophages, was then analysed. We have shown that both enzyme forms bind to the
mannose-6-phosphate receptor on human skin fibroblasts with equal affinity demonstrating that the degree of phosphoryla-
tion of mannose residues in the two forms is similar. However, using rat alveolar macrophages, we found that the
bindingruptake of the two enzymes differs considerably. These results show that differences in glycosylation of lysosomal
enzymes can be an important factor in altering enzyme uptake by different cell types. Thus, producing carbohydrate
modification variants in this way may be useful for altering the distribution of exogenous enzyme in vivo. q 1998 Elsevier
Science B.V. All rights reserved.
Keywords: Receptor mediated binding; Lysosomal storage disorder; Glycosylation
Abbreviations: MPS VI, mucopolysaccharidosis type VI; M6P,
mannose-6-phosphate; CHO-K1, chinese hamster ovary; Asn,
Asparagine; a MEM, minimum essential medium; DMEM, Dul-
becco’s modified Eagle’s medium; 4S, N-acetylgalactosamine-4-
sulphatase; FCS, fetal calf serum; GlcNAc, N-acetyl glu-
cosamine; GlcNAcTI, N-acetylglucosaminyltransferase I; Man,
mannose; cpm, counts per minute; PAGE, polyacrylamide gel
electrophoresis
) Corresponding author. Tel.: q61-8-8204-6373; fax: q61-8-
8204-7100.
1. Introduction
 .M ucopolysaccharidosis M PS type VI
 .Maroteaux–Lamy syndrome is a lysosomal storage
disorder which results from a deficiency of the lyso-
somal enzyme N-acetylgalactosamine-4-sulphatase
 .4S and leads to the storage and urinary excretion of
the glycosaminoglycan, dermatan sulphate. Patients
with this disorder present with skeletal deformities,
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growth retardation, hepatosplenomegaly, corneal
opacity but with normal or near normal neuronal
w xdevelopment 1 . We are currently evaluating enzyme
replacement therapy for MPS VI in a feline model of
w xthis disorder 2 .
The current rationale behind enzyme replacement
therapy for the lysosomal storage disorders is based
on many in vitro studies that show that recombinant
expression systems, most often based on chinese
 .hamster ovary CHO-K1 cells, can be used to pro-
duce enzyme that is efficiently endocytosed by cul-
tured cells resulting in correction of the storage phe-
notype. The endocytosis of recombinant enzyme is
mediated by the well characterised mannose-6-phos-
 .phate M6P marker which is also the signal for
intracellular targeting of soluble lysosomal enzymes
w x3 . The M6P marker is synthesised by the phospho-
rylation of the hydroxyl at the 6-carbon position of
 .specific mannose residues of asparagine Asn -linked
oligosaccharides that contain up to nine mannose
residues. The formation of this M6P signal requires
the activities of two enzymes, N-acetylglucosamine
phosphotransferase and a phosphodiesterase. Initially
the transferase adds an N-acetylglucosamine-1 phos-
phate moiety to the C-6 position of specific mannose
residues, the phosphodiesterase then acts to remove
w xthe N-acetylglucosamine group leaving M6P 4 . Both
modifications occur during transport of the enzyme
through the Golgi apparatus. The M6P residue then
acts as a recognition marker for the cation dependent
w xand cation independent M6P receptors 5,6 responsi-
ble for lysosomal compartmentalisation. Initial stud-
ies evaluating enzyme replacement therapy in animal
models have shown that the distribution of enzyme to
w xdifferent tissues is very unequal 7–9 . This presum-
ably reflects the abundance of the M6P receptor in
different tissues and in their exposure to the circula-
tion.
In addition to the M6P receptor, there are many
other carbohydrate specific receptors which are pre-
w xsent in various amounts on different cell types 10
and which may also prove useful for enzyme target-
ing. In order to investigate the potential for alteration
of cell targeting by modification of enzyme glyco-
sylation, we have generated two glycosylation vari-
ants of recombinant 4S. These were made by express-
ing the 4S cDNA in both wild type CHO-K1 cells
and in the CHO-K1 mutant, Lec1 originally desig-
Fig. 1. Oligosaccharide synthesis on 4S. Schematic representation of reactions leading to the formation of GlcNAc Man GlcNAc in2 3 2
CHO-K1 4S. The GlcNAc Man GlcNAc structure can be further acted upon to form biantennary complex type oligosaccharides.2 3 2
Enzymes responsible for such processing include: 1, manosidase I; 2, N-acetylglucosaminyltransferase I; 3, mannosidase II; 4,
N-acetylglucosaminyltransferase II. As Lec1 4S lacks N-acetylglucosaminyltransferase I activity oligosaccharide processing will
terminate at the Man GlcNAc structure.5 2
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R1 w x.nated Pro-5Wga 3C, 11,12 , lacking N-acetylg-
 .lucosaminyltransferase I GlcNAcTI activity. In wild
type CHO-K1 cells, the glycosylation of lysosomal
enzymes can include both Asn-linked high mannose
oligosaccharides that contain M6P and complex type
oligosaccharides that will not be phosphorylated. The
phosphorylation of mannose residues on an oligo-
saccharide chain prevents the build up of such com-
plex type oligosaccharides on those particular arms.
Synthesis of complex type oligosaccharides is initi-
 .ated by the removal of a 1,2 -linked mannose
residues from the oligosaccharide by mannosidase I
 .producing Man GlcNAc oligosaccharides Fig. 1 .5 2
GlcNAcTI subsequently transfers an N-acetylglu-
cosamine to yield GlcNAc Man GlcNAc . Mannosi-1 5 2
dase II then removes two additional mannose residues
producing a GlcNAc Man GlcNAc structure which1 3 2
can be acted upon by N -acetylgluco -
saminyltransferase II allowing further processing to
 .biantennary complex type oligosaccharides Fig. 1 .
In contrast, the lack of the GlcNAcTI activity in Lec1
cells means that carbohydrate synthesis is halted at
the Man GlcNAc intermediate and is thus, limited5 2
to Asn-linked high mannose oligosaccharides. How-
ever, these structures should also contain M6P.
Cultured human skin fibroblasts express high lev-
w xels of the M6P receptor 13 while rat alveolar
macrophages have been shown to bind glycoproteins
that have terminal sugars with the mannose or glu-
cose configuration to which binding of such glyco-
w xproteins can be inhibited by mannan 14 . In this
study, the binding of the CHO-K1 and Lec1 recombi-
nant 4S variants to cell surface receptors present on
human skin fibroblasts and rat alveolar macrophages
was assessed to see if these two variants of 4S
demonstrate differences in cell receptor affinity
andror endocytosis.
2. Methods
2.1. Materials
The plasmid pRSVN.4S has been described previ-
w xously 15 . Dulbecco’s modified Eagles medium
 .DMEM , minimal essential medium a MEM and
penicillin were purchased from Flow Laboratories
 .Sydney, NSW, Australia . PBS and trypsin were
 .from CSL Parkville, Vic, Australia and fetal calf
 . serum FCS was from Gibco Glen Waverly, Vic,
.Australia . Mannan, mannose-6-phosphate and 4-
methylumbelliferylsulphate were from Sigma St.
. 3Louis, MO, USA . H-L-leucine was from Du Pont
 .North Ryde, NSW, Australia .
2.2. Cell culture and electroporation
CHO-K1 cells were maintained, electroporated and
clonal enzyme producer cell lines identified and iso-
w xlated exactly as described previously 15 . Lec1 cells
 .were obtained from ATCC CRL 1735 and were
 .maintained in a MEMr10% vrv FCS plus antibi-
otics at 378C in a 5% CO atmosphere. Lec1 cells2
were electroporated with pRSVN.4S and a cell line
secreting high levels of 4S was identified exactly as
for CHO-K1 cells.
2.3. Radiolabelling and purification of recombinant
CHO-K1 4S and Lec1 4S
CHO-K1 4S and Lec1 4S cell lines 25 confluent
.T75 fasks of each were labelled with 2.5 mCi of
L- 3H-leucine in 125 ml of leucine free a MEM with
 .  .10% vrv dialysed FCS against PBS , 10-mM
NH Cl and antibiotics, for 48 h. The medium was4
then collected, concentrated and the enzyme purified
by immunoaffinity chromatography as described pre-
w xviously 15 , except that the anti-4S monoclonal anti-
w xbody ASB 58.3 was substituted for ASB 4.1 16 .
The purified labelled enzyme preparation was as-
sayed for tritium on a Wallac 1409 liquid scintillation
counter and for enzyme activity with the fluorogenic
w xsubstrate 4-methylumbelliferylsulphate 17 . Purity
w xwas assessed by SDSrPAGE 18 . Endoglycosidase
H and N-glycosidase F digestions were performed on
10 mg of denatured CHO-K1 4S and Lec1 4S for 12
h with an excess of glycosidase and analysed by
SDSrPAGE.
2.4. Skin fibroblasts
Human diploid fibroblasts were established from
skin biopsies submitted to this hospital for diagnosis
w x19 . Cells were maintained at 378C in a 5% CO2
 .atmosphere in DMEMr10% vrv FCS and antibi-
otics unless otherwise stated. The cell line of normal
( )M. Fuller et al.rBiochimica et Biophysica Acta 1406 1998 283–290286
phenotype used for all binding experiments was SF
4007.
2.5. Isolation of rat al˝eolar macrophages
Alveolar macrophages were isolated from 200–400
g male Wistar rats essentially as described by Brain
w xand Frank 20 , except that the rats were euthanased
 .with an overdose of Pentobarbitone Lethobarb prior
to excision of the lungs. Briefly, the lungs were
excised and the trachea cannulated. The lungs were
then washed internally 10 times with 5-ml physio-
logical saline. The cell concentration in the lung
washings was determined by a Coulter count Tech-
.nicon H.1E and manual differential counts were
performed to confirm the number of macrophages.
 .Macrophage viability was assessed with 0.1% wrv
trypan blue and only lung washings containing greater
than 90% viable macrophages were retained.
Macrophages were used for binding experiments
within 16 h of their isolation from lungs.
2.6. Receptor binding in fibroblasts
Confluent 60 mm dishes of fibroblasts were estab-
lished, the medium was then aspirated, the cell mono-
layer washed twice with PBS and then incubated in
 .DMEM with no FCS including 10% wrv BSA for
6 h at 378C. The dishes were then cooled on ice and
various concentrations of CHO-K1 4S and Lec1 4S,
with and without 5-mM M6P andror 1-mgrml man-
 .nan, were added in 1 ml of DMEMr10% wrv
BSA per dish. Binding was allowed to proceed for 1
h at 48C on a rocking platform to ensure even
distribution of enzyme and inhibitors. The medium
was then removed and the cell monolayer washed
three times with 1-ml ice cold PBS. The monolayer
was extracted with 0.5-ml, 0.5-N KOH and neu-
tralised with 0.5 ml of 0.5 N acetic acid. Cell washes
and extraction were performed at 48C. The medium,
all washes and the cell pellet were each counted on a
Wallac 1409 liquid scintillation counter with 4-ml
LKB Optisafe on the tritium channel. The amount of
enzyme added was calculated from the sum of the
counts recovered in the supernatant, washes and cell
lysate and the amount of enzyme bound was deter-
mined from the number of counts that were in the
cell lysate. The amount of enzyme added was con-
verted from cpm to moles of enzyme using the
 .specific activity cpmrmg reported in Section 3.2
and assuming a molecular weight of 66 kDa for both
enzymes. This was then converted to a molar concen-
tration. The amount of enzyme bound was converted
from cpm to nmolrmin of enzyme activity assuming
a specific activity of 20,000 nmolrminrmg for 4S.
2.7. Receptor binding in macrophages
Half a million rat alveolar macrophages were sedi-
mented and resuspended in 0.5-ml DMEM including
 .10% wrv BSA and no FCS with various concentra-
tions of CHO-K1 4S or Lec1 4S and inhibitors.
Tubes were incubated at 48C or 378C for 1 h on a
rotator and then washed three times by pelleting and
resuspending the cells in PBS. Cells were then lysed
and analysed as described above for fibroblasts.
3. Results
3.1. Recombinant CHO-K1 4S and Lec1 4S
Both recombinant expression systems synthesised
and secreted enzyme at similar levels, approximately
3 mgrl. SDSrPAGE of both enzyme forms of 4S
 .Fig. 2 showed that the Lec1 cell derived enzyme
had a lower molecular weight 42 kDa, compared
.with 45 kDa for CHO-K1 reflecting the effect of the
lack of GlcNAcTI activity on limiting oligosaccha-
ride side chain synthesis. Both enzyme forms appear
to be mature 4S fragments of 42r45, 8 and 7 kDa
.upon denaturing SDS–PAGE rather than the 66 kDa
precursor that would be expected for enzyme isolated
from the medium after secretion from overexpressing
cells. This is most probably a consequence of pro-
tease action during storage of the enzyme prior to
purification and has been noted previously in some
batches of enzyme. As all three fragments found in
mature 4S are linked by disulphide bonds, it is highly
unlikely that the proteolytic clipping observed will
affect the parameters under investigation in this study.
To further define the differences in glycosylation
of CHO-K1 4S and Lec1 4S, they were subjected to
enzymatic deglycosylation with N-glycosidase F and
endoglycosidase H. The results in Fig. 2 show that
following digestion with N-glycosidase F, both
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 .  .Fig. 2. SDSrPAGE of recombinant 4S. SDSrPAGE 10% showing; lane A; the molecular weight standards sizes given in kDa ; lane
B; CHO-K1 4S, lane C; following N-glycosidase F digestion, lane D; following endoglycosidase H digestion, lane E; Lec1 4S, lane F;
following N-glycosidase F digestion and lane G; following endoglycosidase H digestion. Ten micrograms of purified protein from the
culture medium with and without glycosidase digestion were loaded in each lane and the gel was stained with Coomassie Brilliant Blue.
CHO-K1 4S and Lec1 4S are cleaved back to the
same core structure which has an estimated molecular
 .weight of 41 kDa Lanes C and F . However, while
endoglycosidase H digestion of Lec1 4S resulted in a
core structure of the same molecular weight, endogly-
cosidase H digestion of CHO-K1 4S resulted in three
molecular weight forms, one of the same molecular
weight as that from the N-glycosidase F digestion 41
.kDa and two species of slightly higher molecular
 .weight Lane D .
3.2. Radiolabelled 4S
CHO-KI and Lec 4S labelled with 3H leucine were
prepared and purified as described in Section 2. The
concentration of purified CHO 4S was 1333
nmolrminrml and had a specific activity of 6.3=
4 10 cpmrmg assuming a specific activity of 20,000
.nmolrminrmg . The corresponding figures for Lec
4S were 833 nmolrminrml and 6.1=104 cpmrmg.
3.3. Fibroblast receptor binding
The results in Fig. 3 show that there is no apparent
difference in the amount of CHO-K1 4S and Lec1 4S
binding to receptors on fibroblasts at 48C. Binding
appears to be saturable in both cases at approximately
0.02 nmolrminrml. Addition of 5-mM M6P inhibits
fibroblast receptor binding by approximately 70%.
Addition of 1-mgrml mannan has no effect on the
binding of either CHO-K1 or Lec1 4S to skin fibrob-
lasts.
3.4. Rat al˝eolar macrophage receptor binding
Binding of recombinant 4S to macrophages was
performed at 378C to allow the measurement of
enzyme bindingruptake via the mannoserfucose re-
ceptor as this receptor is inactive at 48C. As endocy-
tosis will also occur at this temperature, these experi-
ments will measure the sum of both bound and
endocytosed enzyme. Fig. 4b shows that under these
conditions, Lec1 4S is predominantly boundrendocy-
tosed via the mannose receptor as the addition of
1-mgrml mannan inhibits enzyme bindingruptake
by an average of 60%. The same concentration of
mannan has no discernible effect on CHO-K1 4S
 .uptake Fig. 4a indicating that the bindingrendo-
cytosis of CHO-K1 4S into rat alveolar macrophages
occurs via a mechanism other than the mannose
receptor mediated pathway. This process appears to
be slightly more efficient than the mannose receptor
mediated uptake as CHO-K1 4S is endocytosed at an
approximately 20% higher level than Lec1 4S. A
similar result was observed at 48C with approxi-
mately 50% more CHO-K1 4S than Lec1 4S being
bound and in this instance, the binding of both Lec1
 .4S and CHO-K1 4S is unaffected by mannan Fig. 5
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Fig. 3. CHO-K1 and Lec1 4S binding to fibroblasts. Binding of
purified CHO-K1 4S and Lec1 4S to fibroblasts in 1 h at 48C at
 .  .varying concentrations 0–5 nM of enzyme in the absence v
 .  .and presence of 5 mM M6P B , 1 mgrml mannan ’ and
 .both inhibitors % . Cells were washed and tritium counts deter-
 .mined. Enzyme concentration substrate added was calculated
from the sum of counts in the supernatant, washes and cell lysate.
The quantity of enzyme binding was extrapolated from the counts
 .  .associated with the cell lysate see Section 2 . a shows the
 .results for CHO-K1 4S and b is the same plot for Lec1 4S.
Results plotted are an average of triplicate experiments.
Fig. 4. CHO-K1 and Lec1 4S uptake by macrophages. Uptake of
Lec1 4S and CHO-K1 4S in rat alveolar macrophages in 1 h at
 .378C in concentrations ranging from 0–6 nM in the absence v
 .and presence of 1 mgrml mannan B . Macrophages were
washed by pelleting and resuspension in PBS. Cells were then
 .lysed and analysed as described for fibroblasts. a displays
 .results for CHO-K1 and b for Lec1 4S. Results are an average
of triplicate experiments.
This was anticipated because the mannose receptor
.is inactive at this temperature. . The bindingruptake
of both Lec1 4S and CHO-K1 4S is unaffected by the
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Fig. 5. CHO-K1 4S and Lec1 4S binding to macrophages. A
 .comparison between the amount of CHO-K1 4S v and Lec1
 .4S B binding to macrophages at 48C is displayed. Details of
experimental procedures were the same as described in Fig. 4
except binding, washing and macrophage harvesting undertaken
at 48C. The data plotted are averages of triplicate experiments.
presence of 5-mM M6P at 378C or 48C data not
.shown .
4. Discussion
For effective enzyme replacement therapy for the
lysosomal storage disorders, it is imperative that sig-
nificant amounts of the administered enzyme reaches
all sites of pathology. A number of recombinant
lysosomal enzymes synthesised in CHO-K1 cells have
been shown to be efficiently endocytosed via the
w xM6P receptor on fibroblasts 21,22 . The distribution
of the M6P receptor in vivo makes it clear that some
cells and tissues will not be easily corrected if en-
zyme targeted to this receptor is used for enzyme
w xreplacement therapy 7–9 .
The Lec1 cell line used in this study lacks GlcN-
AcTI activity resulting in the synthesis of high man-
nose oligosaccharide side chains being blocked at the
 .Man GlcNAc intermediate Fig. 1 . Such structures5 2
on 4S will be substrates for the N-acetylglucosamine
phosphotransferase and so Lec1 4S will be modified
to contain M6P residues. The major difference be-
tween CHO-K1 4S and Lec1 4S is therefore, likely to
be the presence of more exposed mannose residues
and the lack of biantennary complex chains on the
Lec1 4S. The analysis of the carbohydrate structures
by N-glycosidase F and endoglycosidase H digestion
supports this contention. N-glycosidase F cleaves all
N-linked oligosaccharide leaving just the polypeptide
chain. Digestion of both CHO-K1 4S and Lec1 4S
results in a product of the same molecular weight 41
.kDa which is the expected size of the polypeptide
core. This result shows that the difference in molecu-
 .lar weight between CHO-K1 4S and Lec1 4S 3 kDa
is solely due to differences in glycosylation. Endogly-
cosidase H cleaves only high mannose and limited
w xhybrid structures 23 leaving a single GlcNAc residue
attached to the polypeptide chain. As expected Lec1
 .4S is cleaved back to the same core size 41 kDa
with N-glycosidase F, confirming that the carbo-
hydrate structures are entirely high mannose oligo-
saccharides. In contrast, endoglycosidase H digestion
of CHO-K1 4S produces a mixture of molecular
weight species indicating that some of the molecules
contain biantennary complex oligosaccharide chains.
The efficient binding of Lec1 as well as CHO-K1
4S via the M6P receptor on fibroblasts and the uptake
of the Lec1 enzyme by the mannoserfucose receptor
on alveolar macrophages is therefore, easily under-
stood in light of the above results. Nevertheless, the
behaviour of the CHO-K1 4S in the macrophage
bindingruptake experiments is unexpected. Although
the lack of significant bindingruptake of CHO-K1
 .4S as opposed to the Lec1 4S via the mannose
receptor on alveolar macrophages can be interpreted
as a result of the masking of mannose structures by
biantenary complexes, the presence of what appears
to be an alternative and more efficient bindingrup-
take mechanism for CHO-K1 4S into macrophages
could not.
The mechanism of the mannan independent up-
takerbinding of CHO-K1 4S observed at 378C is
unknown at this stage and the possibility that it is not
a receptor mediated process cannot be excluded. Cells
contain numerous carbohydrate receptors and even
though a number of specific receptors have been
w xidentified, there are many that have not 24 . We
therefore conclude that there is a carbohydrate struc-
ture that is unique to the CHO-K1 4S that is recog-
nised by an efficient endocytic process and that this
is distinct from the w ell characterised
mannoserfucose receptor. The results of binding
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studies using alveolar macrophages that were per-
formed at 48C also demonstrate that both enzyme
forms can be recognised by systems other than the
mannoserfucose and M6P receptors. Again, binding
of the CHO-K1 4S appears to be more efficient than
that of the Lec1 4S although the observed differences
are relatively small.
These results demonstrate that the differences in
glycosylation of recombinant 4S resulting from ex-
pression in CHO-K1 and Lec1 cells alter the recogni-
tion of 4S by alveolar macrophages. These cells
display a number of defined and undefined carbo-
hydrate receptors and it is unknown which of these, if
any, may be involved in the observed phenomenon.
In contrast, no difference in recognition of the two
forms of 4S by skin fibroblasts, in which uptake is
mediated by the M6P receptor, was observed.
It is therefore clear, from this and other studies
w x25,26 , that the potential exists for significantly alter-
ing the cellular recognition of recombinant proteins
by expression in cell types with defined glycosylation
defects but that although the oligosaccharide side
chain structures that will result can, to a certain
extent, be predicted, the behaviour of the products in
biological systems is more difficult to anticipate. The
effect of such changes on the tissue distribution of
enzyme in vivo and any resulting change in the
efficacy of enzyme replacement therapy in altering
the development of pathology in various tissues in
lysosomal storage disorders will thus, require careful
evaluation in suitable animal models.
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